Cogent Biosciences, Inc. (COGT) has submitted a New Drug Application (NDA) to the FDA for Bezuclastinib, targeting patients with Gastrointestinal Stromal Tumors (GIST) previously treated with Imatinib. This submission follows the FDA’s acceptance of another NDA for the same drug in Non-Advanced Systemic Mastocytosis. The NDA for GIST is backed by promising results from the Phase 3 PEAK trial, which demonstrated a 50% reduction in disease progression risk compared to the current standard of care.

This development is significant for Cogent’s stock performance and the biotech sector, as successful FDA approvals can lead to substantial revenue growth and market share. Analysts remain optimistic, with Wedbush reiterating an OUTPERFORM rating and a price target of $55. The company’s strong cash position of $900.8 million is expected to sustain operations through 2028, allowing for continued investment in clinical trials.

For market professionals, the key takeaway is that Bezuclastinib’s potential approval could reshape treatment protocols for GIST, making Cogent a stock to watch as it navigates upcoming milestones and trial results.

Source: nasdaq.com